Simultaneously, the median PFS and OS in patients with different tumor site (left colon vs. right colon), KRAS status (wide type vs. mutant), metastatic site (with liver metastasis vs. without liver metastasis) and prior regorafenib therapy (Yes vs. No) were also compared, no statistical differences were found between groups with different tumor site, KRAS status and with or without prior regorafenib therapy (Figure 2). Here, KRAS is linked to neoplasm.